These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21266523)

  • 1. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.
    Wright JL; Kwon EM; Ostrander EA; Montgomery RB; Lin DW; Vessella R; Stanford JL; Mostaghel EA
    Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):619-27. PubMed ID: 21266523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.
    Fujimoto N; Kubo T; Inatomi H; Bui HT; Shiota M; Sho T; Matsumoto T
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):336-40. PubMed ID: 23896625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
    Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
    J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis.
    Rajanala SH; Plym A; Vaselkiv JB; Ebot EM; Matsoukas K; Lin Z; Chakraborty G; Markt SC; Penney KL; Lee GM; Mucci LA; Kantoff PW; Stopsack KH
    Carcinogenesis; 2024 Feb; 45(1-2):35-44. PubMed ID: 37856781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
    Alsinnawi M; Zhang A; Bianchi-Frias D; Burns J; Cho E; Zhang X; Sowalsky A; Ye H; Slee AE; True L; Porter C; Taplin ME; Balk S; Nelson PS; Montgomery RB; Mostaghel EA
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):560-568. PubMed ID: 30890759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.
    Namgoong S; Cheong HS; Kim JO; Kim LH; Na HS; Koh IS; Chung MW; Shin HD
    Environ Toxicol Pharmacol; 2015 Nov; 40(3):692-7. PubMed ID: 26409184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Tissue Abiraterone Levels and
    Mostaghel EA; Cho E; Zhang A; Alyamani M; Kaipainen A; Green S; Marck BT; Sharifi N; Wright JL; Gulati R; True LD; Loda M; Matsumoto AM; Tamae D; Penning TN; Balk SP; Kantoff PW; Nelson PS; Taplin ME; Montgomery RB
    Clin Cancer Res; 2017 Aug; 23(16):4592-4601. PubMed ID: 28389510
    [No Abstract]   [Full Text] [Related]  

  • 8. Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.
    Laitinen A; Niemi M
    Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):9-13. PubMed ID: 20560925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Suzuki T; Habuchi T
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1161-9. PubMed ID: 17906856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLCO1B1, SLCO2B1, and SLCO1B3 polymorphisms and susceptibility to bladder cancer risk.
    Bui HT; Fujimoto N; Kubo T; Inatomi H; Matsumoto T
    Cancer Invest; 2014 Jul; 32(6):256-61. PubMed ID: 24762081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
    Wang X; Harshman LC; Xie W; Nakabayashi M; Qu F; Pomerantz MM; Lee GS; Kantoff PW
    J Clin Oncol; 2016 Feb; 34(4):352-9. PubMed ID: 26668348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
    Hamada A; Sissung T; Price DK; Danesi R; Chau CH; Sharifi N; Venzon D; Maeda K; Nagao K; Sparreboom A; Mitsuya H; Dahut WL; Figg WD
    Clin Cancer Res; 2008 Jun; 14(11):3312-8. PubMed ID: 18519758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of OATP transporters in steroid uptake by prostate cancer cells in vivo.
    Green SM; Kaipainen A; Bullock K; Zhang A; Lucas JM; Matson C; Banks WA; Mostaghel EA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):20-27. PubMed ID: 27645128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OATP1B3-1B7, a novel organic anion transporting polypeptide, is modulated by FXR ligands and transports bile acids.
    Malagnino V; Hussner J; Issa A; Midzic A; Meyer Zu Schwabedissen HE
    Am J Physiol Gastrointest Liver Physiol; 2019 Dec; 317(6):G751-G762. PubMed ID: 31509437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.
    Sissung TM; Ley AM; Strope JD; McCrea EM; Beedie S; Peer CJ; Shukla S; van Velkinburgh J; Reece K; Troutman S; Campbell T; Fernandez E; Huang P; Smith J; Thakkar N; Venzon DJ; Brenner S; Lee W; Merino M; Luo J; Jager W; Price DK; Chau CH; Figg WD
    Mol Cancer Res; 2017 Aug; 15(8):1096-1105. PubMed ID: 28389619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.
    Endo S; Fukahori A; Tokuhiro S; Shinagawa A; Walker J; Yoshihara K; Ishizuka H; Ieiri I; Sugiyama Y
    J Hum Genet; 2012 Aug; 57(8):531-44. PubMed ID: 22695893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline Variant in
    Hahn AW; Gill DM; Poole A; Nussenzveig RH; Wilson S; Farnham JM; Stephenson RA; Cannon-Albright LA; Maughan BL; Agarwal N
    Mol Cancer Ther; 2019 Mar; 18(3):726-729. PubMed ID: 30587554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.